Roche Holding Ltd · SIX:RO
Roche — J.P. Morgan 42nd Annual Healthcare Conference 2024
37 slides from Roche's conference presentation, Jan 9, 2024
Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Entering the next growth cycle
Entering the next growth cycle Alan Hippe | CFO Roche J.P.Morgan Healthcare Conference, 9 January 2024
Slide 4: Innovation strategy
Innovation strategy Upcoming opportunities: - Pharma - Diagnostics Outlook
Slide 5: Our achievements
Our achievements Roche is continuously shifting the standard of care A legacy of patient and business …with a track record of establishing standard of care impact… across new therapeutic areas blockbuster drugs in 2022, 16 up from 7 in 2012 in neurology and #1 hemophilia A1 First and only First and
Slide 6: Young marketed and diversified portfolio driving Pharma growth
Young marketed and diversified portfolio driving Pharma growth Keeping historic launch momentum with two NMEs approved in 2023 CHFm % of Pharma Sales** 18,000 50% 16,000 42% 14,000 12,000 34% 10,000 23% 8,000 * 6,000 4,000 2,000 0 YTD Sep 2020 YTD Sep 2021 YTD Sep 2022 YTD Sep 2023 Potential NME app
Slide 7: Reallocating significant resources to R&D
Reallocating significant resources to R&D While defending margins and managing an exceptional patent cliff Roche Group growth FY 2022 vs. FY 2018 Note: Effective 1 January 2023, the Group made presentational and cost allocation changes to the income statement. The comparative information for 2022 wa
Slide 8: Pharma pipeline assets segmented by innovation potential
Pharma pipeline assets segmented by innovation potential Roche ranks #2 having 36 NMEs with first-in-class potential Total number of pipeline assets by innovation potential*, # First-in-class Fast-follower Others* Peer 1 45 11 15 36 17 45 98 Peer 2 34 7 20 Peer 3 33 23 21 Peer 4 29 7 60 Peer 5 25 10
Slide 9: R&D focus areas to speed up delivery of our medicines
R&D focus areas to speed up delivery of our medicines 1 2 3 Set ambitious Strengthen portfolio Transform portfolio R&D objectives framework management & governance 4 5 6 Access the best Optimize R&D engines and Evolve talent, culture and external innovation invest in emerging technologies mindset to
Slide 10: Lab in a loop: Integrating our levers
Lab in a loop: Integrating our levers to build the portfolio of the future Human biology • AI/ML & • High resolution therapeutic • Extreme scale modalities 10
Slide 11: Pipeline acceleration via partnering
Pipeline acceleration via partnering Deals of the past two years increasingly focused on clinical stage NMEs* H2 2023 Development stage Current Immunology Cardiovascular & Metabolism Oncology / Hematology Ophthalmology Positive proof of concept data at time of deal development stage *Table shows cli
Slide 12: Building blocks for future growth through the end of the decade
Building blocks for future growth through the end of the decade Recent acquisitions add significant upside potential Carmot Alnylam Therapeutics Oncology / Hematology partnership acquisition Neuroscience Emerging assets from early Ophthalmology pipeline and BD Immunology CVM CT-388 / Telavant anti-I
Slide 13: Upcoming opportunities: Pharma
Innovation strategy Upcoming opportunities: - Pharma - Diagnostics Outlook
Slide 14: Roche portfolio: Diversifying & establishing leadership positions
Roche portfolio: Diversifying & establishing leadership positions Leadership through medicines setting new standards of care Oncology Neuroscience Immunology Haemophilia A Ophthalmology Infectious diseases Other pharma Diagnostics Sept YTD reported sales; Growth rates at CER (Constant Exchange Rates
Slide 15: Roche portfolio: Diverse growth opportunities ahead
Roche portfolio: Diverse growth opportunities ahead Key pipeline projects with upcoming near-term news flow • Mass spectrometry • Malignant Hematology: • CGM o Lunsumio, Columvi, Polivy in NHL • NGS • Solid tumors: o Inovalisib and giredestrant in breast cancer o Tiragolumab in solid tumors o Divara
Slide 16: Roche portfolio: Diverse growth opportunities ahead
Roche portfolio: Diverse growth opportunities ahead Key pipeline projects with upcoming near-term news flow • Mass spectrometry • Malignant Hematology: • CGM o Lunsumio, Columvi, Polivy in NHL • NGS • Solid tumors: o Inovalisib and giredestrant in breast cancer o Tiragolumab in solid tumors o Divara
Slide 17: Hematology: Portfolio rejuvenation leading to growth rebound
Hematology Hematology: Portfolio rejuvenation leading to growth rebound Driven by diverse portfolio and broad pipeline Roche hematology franchise sales** CHFm YoY CER growth CAGR: +14% 12,000 MabThera/Rituxan 10,000 Gazyva/Gazyvaro -10% +9% 8,000 -8% Hemlibra Polivy 6,000 Lunsumio 4,000 Columvi Othe
Slide 18: Malignant hematology: Growing diversified portfolio
Hematology Malignant hematology: Growing diversified portfolio Hematologic tumor cases by subtype1 Ph III clinical development overview On-market portfolio 3% Pipeline molecules Ph I Ph II Ph III 12% 9% cevostamab Columvi + chemo (STARGLO) in 2L+ DLBCL 2024 7% forimtamig 14% Lunsumio + Polivy (SUNMO
Slide 19: Lunsumio and Columvi: Strong launches in 3L+ setting
Hematology Lunsumio and Columvi: Strong launches in 3L+ setting Off-the-shelf, fixed duration treatments with simple dosing schedule Establishing as new SoC in 3L+ FL Successful launch in 3L+ DLBCL • Approved in 46 countries, reimbursed in 8 countries including US, • Approved in 38 countries includi
Slide 20: Crovalimab: Global filing in PNH, first approval expected H1 2024
Hematology Crovalimab: Global filing in PNH, first approval expected H1 2024 PRO and pooled safety data reinforce positive Ph III (COMMODORE) results Broad development program Treatment benefit in PNH supported by PRO and safety data FACIT-Fatigue scores from baseline to Week 25 ASH 2023 PNH C5i-naï
Slide 21: Breast cancer: Opportunities emerging to expand beyond HER2+
Oncology solid tumors Breast cancer: Opportunities emerging to expand beyond HER2+ Breast cancer cases by subtype1 Ph III clinical development overview Novel mechanisms and technologies Ph I Ph II Ph III On-market portfolio Pipeline molecules Giredestrant + palbociclib (perservERA) in 1L ER+/HER2- m
Slide 22: Inavolisib in PI3K-mutant HR+ breast cancer
Oncology solid tumors Inavolisib in PI3K-mutant HR+ breast cancer Positive Ph III results in 1L with a PFS HR of 0.43 to be filed in US/EU Potential best-in-class PI3Kα inhibitor Ph III (INAVIO120) results: Potency/selectivity (inavolisib vs. alpelisib) Progeression free survival (PFS) 58 Pi3Kα pote
Slide 23: Solid tumors: Tiragolumab program continues to expand
Oncology solid tumors Solid tumors: Tiragolumab program continues to expand Continued confidence in aTIGIT biological activity based on evidence to date First-in-class anti-TIGIT mAb Clinical development program • Tiragolumab blocks the binding of TIGIT to its ligand PVR • Tiragolumab activates T-ce
Slide 24: Roche portfolio: Diverse growth opportunities ahead
Roche portfolio: Diverse growth opportunities ahead Key pipeline projects with upcoming near-term news flow • Mass spectrometry • Malignant Hematology: • CGM o Lunsumio, Columvi, Polivy in NHL • NGS • Solid tumors: o Inovalisib and giredestrant in breast cancer o Tiragolumab in solid tumors o Divara
Slide 25: Trontinemab in Alzheimer's disease
Neuroscience Trontinemab in Alzheimer’s disease First dose finding data for BrainshuttleTM anti-Aβ presented at CTAD Trontinemab Trontinemab is differentiated from conventional anti-Aβ mAbs (BrainshuttleTM anti-Aβ Ab) and other brain delivery technologies Blood BBB Brain tissue Homogeneous brain Inv
Slide 26: Trontinemab clears amyloid more rapidly than conventional mAbs
Neuroscience Trontinemab clears amyloid more rapidly than conventional mAbs BrainshuttleTM AD study results in comparison to other anti-Aβ mAb PhIII trial results Amyloid PET positivity treshold (24 CL) Gantenerumab GRADUATE I /II: presentation at CTAD 2022, publication in preparation; Lecanemab CLA
Slide 27: Roche portfolio: Diverse growth opportunities ahead
Roche portfolio: Diverse growth opportunities ahead Key pipeline projects with upcoming near-term news flow • Mass spectrometry • Malignant Hematology: • CGM o Lunsumio, Columvi, Polivy in NHL • NGS • Solid tumors: o Inovalisib and giredestrant in breast cancer o Tiragolumab in solid tumors o Divara
Slide 28: Ophthalmology: Pipeline gaining momentum with new data in 2024
Ophthalmology Ophthalmology: Pipeline gaining momentum with new data in 2024 Susvimo to be relaunched in AMD and filed in DME and DR in 2024 in the US Phase I Phase II Phase III Launched NME anti-IL-6 Vabysmo Vabysmo RG6351 RG6179 RG7716 RG7716 Retinal disease DME BRVO nAMD NME OpRegen1 Vabysmo Vaby
Slide 29: Roche portfolio: Diverse growth opportunities ahead
Roche portfolio: Diverse growth opportunities ahead Key pipeline projects with upcoming near-term news flow • Mass spectrometry • Malignant Hematology: • CGM o Lunsumio, Columvi, Polivy in NHL • NGS • Solid tumors: o Inovalisib and giredestrant in breast cancer o Tiragolumab in solid tumors o Divara
Slide 30: Immunology: Gazyva Ph III results in lupus nephritis in 2024
Immunology Immunology: Gaza Ph III results in lupus nephritis in 2024 Potential benefit in autoimmune diseases through sustained B cell depletion Gazyva Ph II (NOBILITY) results in LN1 Clinical trial program (glycoengineered anti-CD20 mAb) Complete renal response Type II anti-CD20 region Indication
Slide 31: Roche portfolio: Diverse growth opportunities ahead
Roche portfolio: Diverse growth opportunities ahead Key pipeline projects with upcoming near-term news flow • Mass spectrometry • Malignant Hematology: • CGM o Lunsumio, Columvi, Polivy in NHL • NGS • Solid tumors: o Inovalisib and giredestrant in breast cancer o Tiragolumab in solid tumors o Divara
Slide 32: Important launches in Diagnostics from 2024 onwards
Important launches in Diagnostics from 2024 onwards Diagnostics to deliver mid to high single digit growth in coming years Continuous glucose Next generation Core & Molecular Lab Mass spectrometry monitoring (CGM) sequencing (NGS) • Menu expansion driving growth, • First fully integrated and • Subcu
Slide 33: IR Diagnostics Day in London on May 22nd
IR Diagnostics Day in London on May 22nd Neuroscience Update Digitalization Day ASH Update Diagnostics Day Oct 30 Nov 29 Dec 12 May 22, 2024 Virtual event Virtual event Virtual event London & virtual • Covering ECTRIMS & CTAD data: • Presenting Roche digital efforts • Key data submitted: • Deep-dive
Slide 34: Outlook
Innovation strategy Upcoming opportunities: - Pharma - Diagnostics Outlook
Slide 35: Pipeline outlook: Key late-stage assets with 1bn+ sales potential
Pipeline outlook: Key late-stage assets with 1bn+ sales potential* Oncology, Neuroscience, Immunology, Hematology Cardiometabolic Ophthalmology tiragolumab Elevidys astegolimab NSCLC, HCC, ESCC, SCCHN DMD COPD 9 late-stage NMEs with giredestrant fenebrutinib ASO Factor B CHF>2 bn each in peak HR+ BC
Slide 36: FY 2023 guidance confirmed
FY 2023 guidance confirmed Group sales growth1 Low single digit decline Core EPS growth1 Broadly in line with sales decline Dividend outlook Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) 36
Slide 37: Doing now what patients need next
Doing now what patients need next
Roche — J.P. Morgan 42nd Annual Healthcare Conference 2024 on 6ix